Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200135 | 1.00 | RAB9A (0.52) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL5062929 | 1.00 | RAB9A (0.52) | RAB9ANPC1HPGDALDH1A1POLB | |
| Glycine SCHEMBL11339638 | 0.90 | ITGB3 (0.45) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL3719428 | 0.85 | TDP1 (0.50) | RAB9ANPC1ALDH1A1POLBGAA | |
| SCHEMBL411627 | 0.85 | TDP1 (0.50) | RAB9ANPC1ALDH1A1POLBGAA | |
| SCHEMBL5968639 | 0.83 | POLB (0.50) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL11194641 | 0.81 | RAB9A (0.48) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL28246899 | 0.81 | RAB9A (0.48) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL11194644 | 0.81 | RAB9A (0.48) | RAB9ANPC1HPGDALDH1A1POLB | |
| SCHEMBL5323369 | 0.81 | HPGD (0.49) | RAB9ANPC1HPGDALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4154960-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | claimed |
| CN-119823223-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113396218-B | Engineered transaminase polypeptides | 科德克希思公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118829646-A | Apelin peptide energy macrocycle and application thereof | SOCPRA健康与人文科学有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-117362188-A | Synthesis method of alpha-substituted deuterated amino acid ester | 广州医科大学 | 2024-01-09 | — | — | CN | disclosed |
| EP-4136102-A1 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | I2O Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021212023-A1 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | INTARCIA THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-07-04 | — | — | US | disclosed |
| WO-2017072759-A1 | CAPSULES AND PARTICLES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-04 | — | — | WO | disclosed |
| CN-106573073-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2017-04-19 | — | — | CN | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1044214-A1 | METHOD FOR BINDING ALBUMIN AND MEANS TO BE USED IN THE METHOD | Amersham Pharmacia Biotech AB (SE) | 2000-10-18 | — | — | EP | disclosed |
| US-5994507-A | CONTACTING AQUEOUS LIQUID CONTAINING ALBUMIN WITH A COMPOUND CONTAINING THE SCAFFOLD--C(=O)-NH-C(=C-)-C(=O)- AND HAVING BEEN PRE-CHECKED TO BIND TO THE ALBUMIN; FOR REMOVAL OF ALBUMIN FROM A SOLUTION OR FOR PURIFICATION OF ALBUMIN | AMERSHAM PHARMACIA BIOTECH AB (SE) | 1999-11-30 | — | — | US | disclosed |
| EP-0567470-B1 | PSEUDOMONAS PEPTIDE COMPOSITION AND METHOD FOR PRODUCING THE SAME | SYNTHETIC PEPTIDES INC (CA) | 1999-09-15 | — | — | EP | disclosed |
| WO-1999033860-A1 | METHOD FOR BINDING ALBUMIN AND MEANS TO BE USED IN THE METHOD | AMERSHAM PHARMACIA BIOTECH AB (SE) | 1999-07-08 | — | — | WO | disclosed |
| US-5494672-A | HAVING SEQUENCE CORRESPONDING TO C-TERMINAL PORTION OF THE PSEUDOMONAS AERUGINOSA PILIN PROTEIN; VACCINE | S.P.I. SYNTHETIC PEPTIDES INCORPORATED (CA) | 1996-02-27 | — | — | US | disclosed |
| EP-0567470-A1 | PSEUDOMONAS PEPTIDE COMPOSITION AND METHOD FOR PRODUCING THE SAME | S.P.I. SYNTHETIC PEPTIDES INCORPORATED (CA) | 1993-11-03 | — | — | EP | disclosed |
| WO-1992012169-A1 | PSEUDOMONAS PEPTIDE COMPOSITION AND METHOD FOR PRODUCING THE SAME | S.P.I. SYNTHETIC PEPTIDES INCORPORATED (CA) | 1992-07-23 | — | — | WO | disclosed |
| US-4435329-A | ANTIHYPERTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201349-A1 | CAPSULES AND PARTICLES AND USES THEREOF | ALG1, LPO, FUT5 | RAB9A 1743/4885NPC1 2417/4885HPGD 2339/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | RAB9A 2849/4885NPC1 4562/4885HPGD 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.